1. Musings on the current state of COVID-19 modeling and reporting

   • Peter L. Bonate

   Editorial 29 May 2020 Pages: 183 - 185

2. Hydroxychloroquine and azithromycin as potential treatments for COVID-19; clinical status impacts the outcome

   • Malek Okour
   • Mahmoud Al-Kofahi
   • Daren Austin

   Commentary 13 May 2020 Pages: 187 - 188

   

3. Model based approach for estimating the dosage regimen of indomethacin a potential antiviral treatment of patients infected with SARS CoV-2

   • Roberto Gomeni
   • Tianhong Xu
   • Françoise Bressolle-Gomeni

   Original Paper Open access 20 May 2020 Pages: 189 - 198

   

4. Use of normalized prediction distribution errors for assessing population physiologically-based pharmacokinetic model adequacy

   • Anil R. Maharaj
   • Huali Wu
   • Michael Cohen-Wolkowiez

   Original Paper 22 April 2020 Pages: 199 - 218

   

5. Assessing parameter uncertainty in small-n pharmacometric analyses: value of the log-likelihood profiling-based sampling importance resampling (LLP-SIR) technique

   • Astrid Broeker
   • Sebastian G. Wicha

   Original Paper Open access 04 April 2020 Pages: 219 - 228

   

6. Quantification of the endogenous growth hormone and prolactin lowering effects of a somatostatin-dopamine chimera using population PK/PD modeling

   • Michiel J. van Esdonk
   • Jacobus Burggraaf
   • Jasper Stevens

   Original Paper Open access 04 April 2020 Pages: 229 - 239

   

7. A longitudinal item response model for Aberrant Behavior Checklist (ABC) data from children with autism

   • Elham Haem
   • Marziyeh Doostfatemeh
   • Mats O. Karlsson

   Original Paper 13 April 2020 Pages: 241 - 253

   

8. A clinical population pharmacokinetic/pharmacodynamic model for BIIB059, a monoclonal antibody for the treatment of systemic and cutaneous lupus erythematosus

   • Sonja Hartmann
   • Konstantinos Biliouris
   • Mirjam N. Trame

   Original Paper 25 April 2020 Pages: 255 - 266